Pioneering ‘gene silencing drug’ for Alzheimer’s disease shows promise
June 15, 2023 | Histopathology
Over the duration of the study, the team examined two forms of tau protein. They discovered that those who received the highest dosage showed greater than 50% reduction in total tau and phosphor tau levels after 24 weeks.
Researchers have to perform trials on larger groups and a more diverse population of patients to confirm whether it leads to significant clinical benefits and to understand the extent to which the drug is able to slow the disease’s progression.
Back To Top